Algernon Announces Positive Feedback on its Planned Phase 1/2a DMT Human Stroke Study

Algernon Pharmaceuticals Inc. a clinical stage pharmaceutical development company, is pleased to announce that it has received positive feedback at a scientific advice meeting from the United Kingdom Medicines and Healthcare Products Regulatory Agency.

Compound DMT
Visit article
Category Press Release
?>